Loading search results
SPEED
Sponsor study identifier
Secondary identifiers
REGISTRY · ID RCB
observational
30
1 country
1
Study Start
January 10, 2018
Actual (reported)Primary Completion
January 10, 2019
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
January 10, 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
The process of developing Gamma Knife radiosurgery treatment plans is today very dependent on the level of human expertise resulting in a great heterogeneity of the intrinsic qualities of the treatment planning and the quality of care delivered in radiosurgery. The existing reverse planning systems, although they have progressed considerably in recent years, produce results that are still lower than those achieved by an expert. Conventionally, an experienced dosimetric planner will act mainly on the coordinates of the position of the isocenters, on the size of the collimators, sector by sector, and on the irradiation time of each isocenters. In theory, the combination of these variables provides access to billions of combinatorics whose diversity far exceeds the computational capabilities of the human mind. The dosimetric planner therefore uses a very small part of the spectrum of possible patterns by always reproducing a limited number of empirical solutions. The company Intuitive Therapeutics has developed a new mathematical algorithm which can automatically test in a very short time all the combinatorial possibilities and converge very quickly to the solution that best meets the clinical, anatomical and dosimetric objectives defined by the neurosurgeon. The quick processing of the system also allows the operator to modify the constraints to refine the proposed result in real time. The demonstration of the reality of the performances of this algorithm would give the ability to even inexperienced users to develop high performance planning for the benefit of the patient in terms of optimizing the efficacy / toxicity ratio of the radiosurgery treatment results The primary objective is to evaluate comparatively the quality of the schedules produced by the algorithm developed by the company Innovative Therapeutics to those produced by an expert who carried out more than 15000 dosimetric plannings and radiosurgical interventions. The main criterion of comparison is the Paddick index. The secondary criteria for comparison are:
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 10, 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 10, 2018
Actual (reported)April 27, 2018
Actual (reported)May 11, 2018
Actual (reported)January 10, 2019
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
January 10, 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Evaluate comparatively the quality of the schedules produced by the algorithm developed
to show at least the non-inferiority of this new method compared to the expert user based on the Paddick Index. This index has continuous values between 0 and 1, 0 being the worst case and 1 being the ideal solution
one year
dosimetric planning software
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Single-session treated patient with vestibular schwannoma or multiple brain metastases (\> 5) or para-optic meningioma
Assistance Publique Hôpitaux de Marseille
Marseille, 13354, France
Jean-Olivier ARNAUD, Director
ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE
First Submitted
April 27, 2018
First Posted
May 11, 2018
Study Start
January 10, 2018
Actual (reported)Primary Completion
January 10, 2019
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Contact the study team to confirm eligibility.
Study Completion
January 10, 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
May 17, 2018
Record last verified: 2018-04
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: